At a glance
ClinicalIndex Comparison RecordPhase 3Active· 453 enrolled
Drug / intervention
Abemaciclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Abemaciclib and Erlotinib for Non Small Cell Lung Cancer. Active but no longer recruiting, targeting 453 participants across 231 sites in 21 countries.
Detailed Summary
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesArgentina, Austria, Brazil, Canada, China, France, Germany, Greece, Israel, Italy, Japan, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 3Active
2015201620172018201920202021202220232024202520262027
First PostedJun 2014
Enrollment StartOct 2014
Primary CompletionSep 2017
TodayJul 2026
Study CompletionDec 2026
First PostedJun 2, 2014
Enrollment StartOct 3, 2014
Primary CompletionSep 15, 2017
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.1 years ago
Interventions
Abemaciclibdrug
Administered orally
Erlotinibdrug
Administered orally